247 related articles for article (PubMed ID: 22385314)
1. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management.
Pavenski K; Freedman J; Semple JW
Tissue Antigens; 2012 Apr; 79(4):237-45. PubMed ID: 22385314
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of refractoriness to platelet transfusion.
Schiffer CA
Blood Rev; 2001 Dec; 15(4):175-80. PubMed ID: 11792118
[TBL] [Abstract][Full Text] [Related]
3. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; BertÃn P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
4. Clinical aspects of platelet transfusions.
Murphy MF; Waters AH
Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
[TBL] [Abstract][Full Text] [Related]
5. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
6. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
Sandler SG
Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
[TBL] [Abstract][Full Text] [Related]
7. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
[TBL] [Abstract][Full Text] [Related]
8. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
9. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
Stanworth SJ; Navarrete C; Estcourt L; Marsh J
Br J Haematol; 2015 Nov; 171(3):297-305. PubMed ID: 26194869
[TBL] [Abstract][Full Text] [Related]
10. Prevention of platelet alloimmunization.
Slichter SJ
Prog Clin Biol Res; 1986; 211():83-116. PubMed ID: 3515365
[TBL] [Abstract][Full Text] [Related]
11. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
Panch SR; Guo L; Vassallo R
Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
[TBL] [Abstract][Full Text] [Related]
12. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.
Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG
Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645
[TBL] [Abstract][Full Text] [Related]
13. Management of patients refractory to platelet transfusion.
Chockalingam P; Sacher RA
J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
[TBL] [Abstract][Full Text] [Related]
14. Alloimmunization to public HLA antigens in multi-transfused platelet recipients.
MacPherson BR; Hammond PB; Maniscalco CA
Ann Clin Lab Sci; 1986; 16(1):38-44. PubMed ID: 3947028
[TBL] [Abstract][Full Text] [Related]
15. Strategies for managing refractoriness to platelet transfusions.
Dan ME; Schiffer CA
Curr Hematol Rep; 2003 Mar; 2(2):158-64. PubMed ID: 12901147
[TBL] [Abstract][Full Text] [Related]
16. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation.
Toor AA; Choo SY; Little JA
Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572
[TBL] [Abstract][Full Text] [Related]
17. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
18. A mini-review on platelet refractoriness.
Rebulla P
Haematologica; 2005 Feb; 90(2):247-53. PubMed ID: 15710579
[TBL] [Abstract][Full Text] [Related]
19. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
[TBL] [Abstract][Full Text] [Related]
20. [Risk of immunization to blood cells and diagnostic and therapeutic implications].
Kiefel V
Beitr Infusionsther; 1993; 31():44-51. PubMed ID: 7693263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
